Compare SRTA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 495.5M |
| IPO Year | 2019 | 2021 |
| Metric | SRTA | VALN |
|---|---|---|
| Price | $5.38 | $6.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.81 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 955.6K | 78.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 242.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $197,141,000.00 | N/A |
| Revenue This Year | $39.27 | N/A |
| Revenue Next Year | $8.52 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.85 | $4.75 |
| 52 Week High | $6.50 | $12.23 |
| Indicator | SRTA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 59.79 |
| Support Level | $5.23 | $5.03 |
| Resistance Level | $5.55 | $6.60 |
| Average True Range (ATR) | 0.24 | 0.24 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 2.51 | 57.53 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.